<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01331317</url>
  </required_header>
  <id_info>
    <org_study_id>2009-011255-44</org_study_id>
    <nct_id>NCT01331317</nct_id>
  </id_info>
  <brief_title>Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy</brief_title>
  <official_title>The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Rossing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the impact of three months of treatment with an active
      vitamin D analogue on a risk marker for excess overall mortality and cardiovascular
      morbidity/mortality in Type 1 diabetic patients with diabetic kidney disease. The hypothesis
      is that active vitamin D analogue treatment reduces the risk of cardiovascular morbidity and
      mortality in patients with type 1 diabetic kidney disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma NT-proBNP</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Glomerular Filtration Rate (GFR)</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Albumin Excretion Rate</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Paricalcitol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Crossover study between paricalcitol and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>capsule, 1-2 micrograms daily for 90 days</description>
    <arm_group_label>Paricalcitol</arm_group_label>
    <other_name>Zemplar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 years of age

          -  Type 1 diabetes mellitus

          -  Diabetic nephropathy (defined by persistent albuminuria, &gt; 300 mg/24 hr or 200Âµg/min
             in 2 of 3 consecutive samples, presence of diabetic retinopathy and absence of
             clinical or laboratory evidence of other kidney or renal tract disease

          -  Chronic kidney disease stage 3 and 4

          -  S-Parathyroid hormone (s-PTH)&gt; 35pg/ml

          -  Stabile RAAS-blocking and diuretic treatment

        Exclusion Criteria:

          -  Other kidney disease than diabetic nephropathy

          -  Myocardial infarction within the last three months prior to visit 1

          -  Coronary artery revascularization within the last three months prior to visit 1

          -  Transitional cerebral ischemia (TCI) or apoplexia within the last three months prior
             to visit 1

          -  Cardiac Failure (NYHA Class III or IV)

          -  Kidney Failure (GFR &lt;15ml/min), dialysis, kidney transplantation)

          -  Liver disease with serum alanine aminotransferase (ALT&gt;3 x the normal value

          -  Alcohol/drug abuse

          -  Hypercalcemia (serum ionized calcium &gt;1.35 mmol /L)

          -  Medication with phosphate and/or vitamin D-containing medications, which can not be
             paused during the study

          -  Clinical signs of vitamin D toxicity

          -  Pregnant or nursing women

          -  Fertile women not using chemical or mechanical (IUD) contraceptive methods

          -  Current disulfiram treatment

          -  Allergy to the study drug

          -  Patient unable to understand the informed consent

          -  Any other condition or therapy which, in the opinion of the investigator, makes the
             patient not suited for participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lise Tarnow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Steno Diabetes Center A/S</name>
      <address>
        <city>Gentofte</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2010</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <last_update_submitted>April 12, 2012</last_update_submitted>
  <last_update_submitted_qc>April 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center</investigator_affiliation>
    <investigator_full_name>Peter Rossing</investigator_full_name>
    <investigator_title>Senior Physician, DMSc</investigator_title>
  </responsible_party>
  <keyword>Cardiovascular disease and mortality</keyword>
  <keyword>Plasma NTproBNP</keyword>
  <keyword>UAER</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

